Vaxxas Inc

Exhibitor

Vaxxas is a biotechnology company pioneering a high-density microarray patch (HD-MAP) technology to enhance the performance of existing and next-generation vaccines. The HD-MAP has been administered to more than 750 participants across clinical trials, demonstrating strong safety, tolerability, and robust immune responses. Preclinical and clinical data indicate the technology has the potential to deliver all major vaccine types positioning the technology as a universal delivery solution. By targeting immune cells just beneath the skin, the HD-MAP has the potential to achieve stronger protection with smaller doses, while reducing cold-chain requirements and enabling self-administration.

website